March 8, 2021 11:09 AM ESTUpdated 12:27 PM
R&D

Cy­to­Dyn tries to squeeze pos­i­tive news out of a failed Covid-19 study — and shares take a beat­ing

Amber Tong

Cy­to­Dyn re­al­ly, re­al­ly want­ed to put its best foot for­ward.

So much so that, af­ter sit­ting on un­blind­ed Phase IIb/III da­ta on leron­limab in Covid …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

A service from the Financial Times